Fundraising Fox
Myimmune
1 known investors
Find your way into Myimmune
Sign up to see every warm intro you have to Myimmune
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Myimmune team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
MyImmune develops AI that analyzes adaptive immune repertoire data to identify drug targets, predict patient responses to immunotherapies, and build biomarkers and companion diagnostics. It serves biotech, pharma, and CRO customers working in oncology, autoimmune, and infectious diseases.
Founders & leadership
AS
Ayan SenguptaCo-Founder and CEOAyan Sengupta is co-founder and CTO of MyImmune, which develops AI technology to analyze immune system data for drug discovery, patient response prediction, and diagnostic development in oncology, autoimmune, and infectious disease applications.
Investors · 1
Related companies · 7
ImmunaiImmunai develops AMICA, a data platform for decoding the immune system to accelerate drug discovery and development. The company serves pharmaceutical and biotech researchers working on inflammatory and oncological therapies.
InfinimmuneInfinimmune discovers and develops antibody therapeutics using proprietary sequencing technology and AI-powered optimization. The company serves pharmaceutical and biotech partners developing treatments across 350+ disease targets.
Immune-Onc TherapeuticsImmune Onc is a biotechnology company developing medicines to treat patients with hard-to-treat cancers and autoimmune diseases, with expertise in translational medicine and clinical development.
InimmuneInimmune is a clinical-stage biotech company developing immunotherapies for allergy, cancer, infectious, and autoimmune diseases. The company combines immunology and vaccine expertise to advance its clinical and pre-clinical pipeline.
ImmunomeImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
Inmune BioINmune Bio is a clinical-stage biotechnology company developing immunotherapies, including XPro1595, aimed at treating neurodegenerative and psychiatric diseases through a biomarker-directed approach. The company works on translating inflammatory therapies into clinical treatments for neurologic and other diseases.
ImmunitoaiImmunito AI is an in-silico antibody discovery company that combines artificial intelligence with an in-house biological lab to speed up and improve the discovery of antibodies. It serves the biotech and biopharmaceutical industry.
Companies working in the same space as Myimmune.
Frequently asked questions
- What does Myimmune do?
- MyImmune develops AI that analyzes adaptive immune repertoire data to identify drug targets, predict patient responses to immunotherapies, and build biomarkers and companion diagnostics. It serves biotech, pharma, and CRO customers working in oncology, autoimmune, and infectious diseases.
- Who founded Myimmune?
- Myimmune was founded by Ayan Sengupta.
- Who are Myimmune's investors?
- Myimmune's investors include OSAKA University Venture Capital.